Meeting
2014 ASCO Annual Meeting
Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-controlled phase II trial.
Authors
Frederik Marme
National Center for Tumor Diseases, Gynecologic Oncology, Heidelberg, Germany
Frederik Marme , Bernd Gerber , Marcus Schmidt , Volker Jochen Moebus , Frank Gerhard Foerster , Eva-Maria Grischke , Matthias W. Beckmann , Dirk Strumberg , Erich Solomayer , Peter Klare , Christiane Windemuth-Kieselbach , Andreas Schneeweiss
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Clinical Trial Registration Number
EUDRACT-Nr. 2008-001090-15
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 1072)
DOI
10.1200/jco.2014.32.15_suppl.1072
Abstract #
1072
Poster Bd #
165
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research Institute.
First Author: Dana Shelton Thompson
Poster
2011 ASCO Annual Meeting
Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): Results of a Japanese phase II study (n=120).
First Author: Y. Ito
Poster
2011 ASCO Annual Meeting
Outcomes in phase II trials of metastatic breast cancer: Where is the bar?
First Author: A. Kamal
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando